Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 5Melanoma 3Neoplasm Metastasis 2Lung Neoplasms 2Head and Neck Neoplasms 2Glioblastoma 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lymphoma 1Glioma 1Extensive Stage Small Cell Lung Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 16Nivolumab 15Ipilimumab 12cemiplimab 10aldesleukin 6Interleukin-2 6Cyclophosphamide 6fludarabine 5fludarabine phosphate 4encorafenib 4binimetinib 4Blood Specimen Collection 4avelumab 3Sirolimus 3trametinib 2spartalizumab 2lifileucel 2dabrafenib 2atezolizumab 2Vemurafenib 2Surgical Procedures, Operative 2Specimen Handling 2Radiotherapy 2Prednisone 2Niacinamide 2Exercise 2Everolimus 2Dermoscopy 2Biopsy 2urelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Neoplasms × epacadostat × 1 year × Clear all
NCT01604889 2026-04-21

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

Incyte Corporation

Phase 1/2 Terminated
50 enrolled
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡